JP2016500513A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500513A5 JP2016500513A5 JP2015532967A JP2015532967A JP2016500513A5 JP 2016500513 A5 JP2016500513 A5 JP 2016500513A5 JP 2015532967 A JP2015532967 A JP 2015532967A JP 2015532967 A JP2015532967 A JP 2015532967A JP 2016500513 A5 JP2016500513 A5 JP 2016500513A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- active ingredient
- conjugate
- composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 239000004480 active ingredient Substances 0.000 claims 13
- 239000002872 contrast media Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 235000013402 health food Nutrition 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical group [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0104173 | 2012-09-19 | ||
| KR10-2012-0104144 | 2012-09-19 | ||
| KR20120104173 | 2012-09-19 | ||
| KR20120104144 | 2012-09-19 | ||
| KR20120109216 | 2012-09-28 | ||
| KR10-2012-0109207 | 2012-09-28 | ||
| KR20120109207 | 2012-09-28 | ||
| KR10-2012-0109216 | 2012-09-28 | ||
| KR10-2013-0017046 | 2013-02-18 | ||
| KR20130017046 | 2013-02-18 | ||
| PCT/KR2013/008459 WO2014046490A1 (ko) | 2012-09-19 | 2013-09-17 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078286A Division JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500513A JP2016500513A (ja) | 2016-01-14 |
| JP2016500513A5 true JP2016500513A5 (enExample) | 2016-12-08 |
| JP6517692B2 JP6517692B2 (ja) | 2019-05-22 |
Family
ID=50341706
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532967A Active JP6517692B2 (ja) | 2012-09-19 | 2013-09-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2019078286A Active JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020088976A Active JP7007423B2 (ja) | 2012-09-19 | 2020-05-21 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022000896A Active JP7328375B2 (ja) | 2012-09-19 | 2022-01-06 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023127115A Active JP7627726B2 (ja) | 2012-09-19 | 2023-08-03 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078286A Active JP6708770B2 (ja) | 2012-09-19 | 2019-04-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2020088976A Active JP7007423B2 (ja) | 2012-09-19 | 2020-05-21 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2022000896A Active JP7328375B2 (ja) | 2012-09-19 | 2022-01-06 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
| JP2023127115A Active JP7627726B2 (ja) | 2012-09-19 | 2023-08-03 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9572900B2 (enExample) |
| EP (2) | EP2899201B1 (enExample) |
| JP (5) | JP6517692B2 (enExample) |
| KR (1) | KR102201429B1 (enExample) |
| CN (3) | CN104981478B (enExample) |
| ES (2) | ES2758451T3 (enExample) |
| TW (1) | TWI616531B (enExample) |
| WO (1) | WO2014046490A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101997756B1 (ko) | 2012-05-11 | 2019-07-08 | 주식회사 젬백스앤카엘 | 패혈증 예방 또는 치료용 조성물 |
| ES3046661T3 (en) | 2012-05-11 | 2025-12-02 | Gemvax & Kael Co Ltd | Anti-inflammatory peptides and composition comprising the same |
| KR101799904B1 (ko) | 2012-07-11 | 2017-11-22 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| WO2014046478A1 (ko) | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| TWI616530B (zh) * | 2012-09-19 | 2018-03-01 | 傑姆維克斯＆凱爾有限公司 | 穿膜胜肽以及包含該胜肽之共軛物及組成物（一） |
| ES2743919T3 (es) | 2012-09-19 | 2020-02-21 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
| ES2716870T3 (es) | 2013-04-19 | 2019-06-17 | Gemvax & Kael Co Ltd | Composición para el tratamiento y prevención de lesión isquémica |
| EP4063863A1 (en) | 2013-06-07 | 2022-09-28 | Gemvax & Kael Co., Ltd. | Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients |
| TWI539960B (zh) | 2013-06-21 | 2016-07-01 | 凱爾傑姆維克斯有限公司 | 激素分泌調節劑、包括其的組成物以及其用途 |
| CN105899224B (zh) | 2013-10-23 | 2019-12-13 | 珍白斯凯尔有限公司 | 用于治疗和预防良性前列腺增生的组合物 |
| KR102359396B1 (ko) | 2013-11-22 | 2022-02-08 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2015093854A1 (ko) | 2013-12-17 | 2015-06-25 | 주식회사 카엘젬백스 | 전립선 암 치료용 조성물 |
| KR102373603B1 (ko) | 2014-04-11 | 2022-03-14 | 주식회사 젬백스앤카엘 | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| WO2015167067A1 (ko) | 2014-04-30 | 2015-11-05 | 주식회사 카엘젬백스 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| ES2799511T3 (es) | 2015-02-27 | 2020-12-18 | Gemvax & Kael Co Ltd | Péptido para prevenir la pérdida de audición, y composición que lo comprende |
| WO2016190660A1 (ko) | 2015-05-26 | 2016-12-01 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
| US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
| WO2017192761A1 (en) * | 2016-05-03 | 2017-11-09 | The Regents Of The University Of Colorado, A Body Corporate | Propionyl-coa carboxylase compositions and uses thereof |
| KR102042758B1 (ko) * | 2017-06-28 | 2019-11-08 | 주식회사 엘지생활건강 | 경피투과도가 향상된 신경전달물질 조절 펩타이드 화장료 조성물 |
| EP4389893A4 (en) | 2021-08-21 | 2025-09-10 | Takeda Pharmaceuticals Co | PEPTIDE-DRUG CONJUGATE BINDING HUMAN TRANSFERRIN RECEPTOR |
| CN118201966A (zh) | 2021-08-24 | 2024-06-14 | 肽梦想株式会社 | 人转铁蛋白受体结合抗体-肽缀合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846968B1 (en) * | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
| US5738996A (en) * | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| AR009416A1 (es) * | 1996-11-15 | 2000-04-12 | Amgen Inc | Nuevos genes que codifican proeinas de telomerasa |
| GB9705519D0 (en) | 1997-03-18 | 1997-05-07 | Anmat Technology Limited | Activation of peptides |
| KR100581990B1 (ko) * | 1997-07-01 | 2006-05-23 | 캄비아 바이오시스템즈 엘엘씨 | 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도 |
| US7030211B1 (en) * | 1998-07-08 | 2006-04-18 | Gemvax As | Antigenic peptides derived from telomerase |
| US6831060B2 (en) * | 1999-05-07 | 2004-12-14 | Genentech, Inc. | Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same |
| US7078491B1 (en) | 2000-09-21 | 2006-07-18 | Amgen Inc. | Selective binding agents of telomerase |
| AUPR769701A0 (en) * | 2001-09-14 | 2001-10-11 | Li, He | Telomerase inhibitory peptides and uses thereof |
| CN1194007C (zh) * | 2001-10-25 | 2005-03-23 | 北京百泰博创医药科技有限公司 | P6a的代谢产物的分离、合成及其在医学中的应用 |
| US20030143228A1 (en) * | 2001-10-29 | 2003-07-31 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
| EP1575496A4 (en) * | 2002-04-05 | 2008-01-23 | Univ Utah Res Found | COLON TUMOR SPECIFIC BINDING PEPTIDES |
| US8128908B2 (en) | 2004-04-30 | 2012-03-06 | University Of Florida Research Foundation, Inc. | Nanoparticles and their use for multifunctional bioimaging |
| WO2006108211A1 (en) * | 2005-02-25 | 2006-10-19 | The Murdoch Childrens Research Institute | Fragments of von willebrand factor a-related protein |
| EP1748067A1 (en) * | 2005-07-29 | 2007-01-31 | Institut Pasteur | Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes |
| US20090068158A1 (en) * | 2005-12-09 | 2009-03-12 | Medin Jeffrey A | Thymidylate kinase mutants and uses thereof |
| JP2009519033A (ja) | 2005-12-16 | 2009-05-14 | ディアト | 核酸を細胞に送達するための細胞貫通ペプチド結合体 |
| US20100168034A1 (en) | 2006-02-20 | 2010-07-01 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
| CA2651917A1 (en) * | 2006-06-09 | 2007-12-13 | Bio Pur Ag | A method for the detection of enzymatic reactions |
| EP2129682A4 (en) | 2007-01-29 | 2011-07-20 | Procell Therapeutics Inc | NOVEL DOMAINS OF MACROMOLECULE TRANSDUCTION AND METHODS OF IDENTIFICATION AND USES THEREOF |
| US8378070B2 (en) * | 2007-03-12 | 2013-02-19 | Ramot At Tel-Aviv University Ltd. | Peptides for the regulation of neurotransmitter sequestration and release |
| JP5170407B2 (ja) * | 2007-03-30 | 2013-03-27 | 国立大学法人九州工業大学 | 糖尿病合併症検査用試薬 |
| EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
| WO2009025871A1 (en) | 2007-08-23 | 2009-02-26 | University Of Medicine And Dentistry Of Nj | Telomerase reverse transcriptase variant |
| PT2207790E (pt) * | 2007-09-05 | 2013-11-04 | Genentech Inc | Péptidos que contêm arginina c-terminal biologicamente ativos |
| US8252282B2 (en) | 2008-06-19 | 2012-08-28 | University Of Medicine & Dentistry Of New Jersey | Nuclear telomerase reverse transcriptase variant |
| KR20100006939A (ko) * | 2008-07-10 | 2010-01-22 | 한국생명공학연구원 | 융합 단백질 전달을 통한 세포의 리프로그래밍 방법 |
| ES2334315B1 (es) | 2008-07-29 | 2011-02-28 | Universitat Pompeu Fabra | Peptidos con capacidad de penetracion celular y sus usos. |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
| AU2010250452B2 (en) | 2009-05-20 | 2014-06-05 | Toray Industries, Inc. | Cell membrane-permeable peptides |
| EP2289558A1 (en) | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
| ES2751092T3 (es) * | 2010-02-16 | 2020-03-30 | Ultimovacs Asa | Polipéptidos |
| KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
| WO2011150493A1 (en) | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for antimicrobials |
| CN102311493B (zh) * | 2010-07-02 | 2014-06-04 | 中国科学院上海生命科学研究院 | 一种抑制端粒酶活性的肽及其制备方法和应用 |
| KR101348284B1 (ko) | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| ES3046661T3 (en) | 2012-05-11 | 2025-12-02 | Gemvax & Kael Co Ltd | Anti-inflammatory peptides and composition comprising the same |
| KR101799904B1 (ko) * | 2012-07-11 | 2017-11-22 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| ES2743919T3 (es) | 2012-09-19 | 2020-02-21 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
| WO2014046478A1 (ko) * | 2012-09-19 | 2014-03-27 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| EP2899201B1 (en) | 2012-09-19 | 2019-09-11 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| EP4063863A1 (en) | 2013-06-07 | 2022-09-28 | Gemvax & Kael Co., Ltd. | Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients |
| EP3020724A4 (en) | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
| WO2016190660A1 (ko) | 2015-05-26 | 2016-12-01 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| TW201718028A (zh) | 2015-10-13 | 2017-06-01 | 賽米克Ｉｐ有限責任公司 | Ve-鈣黏蛋白結合性生物結合物 |
-
2013
- 2013-09-17 EP EP13838276.7A patent/EP2899201B1/en active Active
- 2013-09-17 JP JP2015532967A patent/JP6517692B2/ja active Active
- 2013-09-17 WO PCT/KR2013/008459 patent/WO2014046490A1/ko not_active Ceased
- 2013-09-17 CN CN201380057894.1A patent/CN104981478B/zh active Active
- 2013-09-17 KR KR1020157009511A patent/KR102201429B1/ko active Active
- 2013-09-17 ES ES13838276T patent/ES2758451T3/es active Active
- 2013-09-17 EP EP19196538.3A patent/EP3611184B1/en active Active
- 2013-09-17 ES ES19196538T patent/ES2999332T3/es active Active
- 2013-09-17 CN CN201710451503.4A patent/CN107312759B/zh active Active
- 2013-09-17 CN CN202111025572.1A patent/CN113699133B/zh active Active
- 2013-09-17 US US14/429,644 patent/US9572900B2/en active Active
- 2013-09-17 TW TW102133730A patent/TWI616531B/zh active
-
2016
- 2016-12-09 US US15/374,805 patent/US10245327B2/en active Active
-
2019
- 2019-02-12 US US16/273,689 patent/US11844845B2/en active Active
- 2019-04-17 JP JP2019078286A patent/JP6708770B2/ja active Active
-
2020
- 2020-05-21 JP JP2020088976A patent/JP7007423B2/ja active Active
-
2022
- 2022-01-06 JP JP2022000896A patent/JP7328375B2/ja active Active
-
2023
- 2023-08-03 JP JP2023127115A patent/JP7627726B2/ja active Active
- 2023-11-06 US US18/502,720 patent/US20240181090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016500513A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| JP2015530404A5 (enExample) | ||
| JP2015530358A5 (enExample) | ||
| He et al. | Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer | |
| Chakraborti et al. | Self-assembly of ferritin: structure, biological function and potential applications in nanotechnology | |
| Wyatt et al. | Applications of pHLIP technology for cancer imaging and therapy | |
| Bhushan et al. | Ferritin nanocages: a novel platform for biomedical applications | |
| Ruan et al. | Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers | |
| Belletti et al. | Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin | |
| Jeevanandam et al. | Advancing aptamers as molecular probes for cancer theranostic applications—the role of molecular dynamics simulation | |
| JP2011037872A5 (enExample) | ||
| Zhu et al. | Application of virus targeting nanocarrier drug delivery system in virus-induced central nervous system disease treatment | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| Wu et al. | Mannan-decorated lipid calcium phosphate nanoparticle vaccine increased the antitumor immune response by modulating the tumor microenvironment | |
| HRP20121016T1 (hr) | Sredstva i postupci za upravljanje interferencijom proteina | |
| JP2010514779A5 (enExample) | ||
| Li et al. | Selective capture and recovery of monoclonal antibodies by self-assembling supramolecular polymers of high affinity for protein binding | |
| Noguchi et al. | Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery | |
| Kim et al. | Designing peptide bunches on nanocage for bispecific or superaffinity targeting | |
| Zou et al. | Expression, purification, and characterization of recombinant human L-chain ferritin | |
| CN103788211A (zh) | 双功能肽、所述双功能肽与核酸分子形成的复合物以及治疗肿瘤的药物组合物 | |
| Lee et al. | Tuning of peptide cytotoxicity with cell penetrating Motif activatable by matrix Metalloproteinase-2 | |
| Gao et al. | Photothermal therapeutic gold nanoparticles loaded with PD-L1 siRNA enhanced killing of NSCLC cells by immune cells | |
| Alsharedeh et al. | Magnetosomes as potential nanocarriers for cancer treatment |